Skip to content


  • Poster presentation
  • Open Access

Effectiveness of the treatment with intravenous pamidronate in children with rheumatic diseases

  • 1,
  • 1 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :P145

  • Published:


  • Steroid
  • Bone Mineral Density
  • Osteoporosis
  • Systemic Lupus Erythematosus
  • Bone Mass


In patients with systemic diseases bone mineral density is diminished due to the underlaying disease, the secondary loss of bone mass, the diminution of mobility and the treatment with steroids. Biphosphonates inhibit bone resorption: they produce reduction of the apoptosis in osteoblasts and induce apoptosis in osteoclasts [1, 2].


To value the effectiveness of the treatment with intravenous pamidronate in children with secondary osteoporosis or osteopenia to rheumatic diseases.

Materials and methods

Retrospective analytical study: 22 children, ages between the 4 and 17 years and clinical diagnosis of osteopenia, osteoporosis, calcinosis secondary to rheumatic diseases (Juvenile Idiopatic Arthritis, Systemic Lupus Erythematosus, Juvenile Dermatomiositis, Overlap Syndrome, Panarteritis Nodosa, Familiar Mediterranean Fever). Criteria of inclusion: the patients had to fulfill the criteria of osteopenia and osteoporosis defined according to z-score or bone mineral density; and the diagnostic criteria of the referred diseases. Information about the underlaying disease, the treatment received and steroids' dose and duration was collected. The administration of intravenous pamidronate was made according to the protocol established by Glorieux et al.


All the patients treated with intravenous pamidronate presented a significant increase in bone mineral density, clinical improvement, decrease of the number of fractures, reduction in bone pain and improvement of the quality of life. In all the patients with calcinosis a reduction was observed and in one patient it even disappeared.

Authors’ Affiliations

Hospital Infantil la Fe, Valencia, Spain


  1. Noguera A, Ros JB, Pavía C, Alcover E, Valls C, Villaronga M, González E: Biphospohonates, a new treatment for glucocorticoid-induced osteoporosis in chidren. J Pediatr Endocrinol Metab. 2003, 16: 529-536.PubMedGoogle Scholar
  2. Shaw NJ, Bishop NJ: Bisphosphonate treatment of bone disease. Arch Dis Child. 2005, 90: 494-9. 10.1136/adc.2003.036590.PubMed CentralView ArticlePubMedGoogle Scholar


© Marco et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.